Literature DB >> 7585572

Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer.

L Kaklamanis1, R Leek, M Koukourakis, K C Gatter, A L Harris.   

Abstract

We studied by immunohistochemistry the HLA-allelic, beta 2-microglobulin, and TAP-1 expression in primary breast carcinomas and related lymph node metastases. Thirty-three of the primary tumors and 44% of the lymph node metastases had a complete HLA class I loss. The higher incidence of antigenic loss in metastatic tumors suggests that recognition of HLA class I antigens by the host immunity could have an important role in the metastatic evolution of breast cancer. We observed a simultaneous defective expression of all three components involved in HLA class I expression. Since the controlling genes of heavy chain and TAP-1 are located in different chromosome than beta 2-microglobulin, it could be that a common factor exists regulating HLA class I antigenic expression. Five of 25 (20%) primary and metastatic tumors from HLA-A2-positive individuals also had a selective loss. The high incidence of HLA class I loss in breast cancer patients shows that adjuvant immunotherapy to induce HLA class I expression could be of value in a subgroup of patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7585572

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

Review 1.  Tumor-associated macrophages in breast cancer.

Authors:  Russell D Leek; Adrian L Harris
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Role of the HLA System in the Pathogenesis of Dupuytren's Disease.

Authors:  Sara McCarty; Farhatullah Syed; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2010-02-09

3.  Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines.

Authors:  H Pandha; A Rigg; J John; N Lemoine
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

4.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.

Authors:  T Kageshita; S Hirai; T Ono; D J Hicklin; S Ferrone
Journal:  Am J Pathol       Date:  1999-03       Impact factor: 4.307

5.  Differential diagnostic significance of the paucity of HLA-I antigens on metastatic breast carcinoma cells in effusions.

Authors:  E Magyarosy; W J Martin; E W Chu; S E Martin
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

6.  MHC class I and class II molecules are expressed in both human and mouse prostate tumor microenvironment.

Authors:  Navreet K Nanda; Lynn Birch; Norman M Greenberg; Gail S Prins
Journal:  Prostate       Date:  2006-09-01       Impact factor: 4.104

7.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

8.  Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.

Authors:  Masanao Saio; Matt Teicher; Gaynor Campbell; Helen Feiner; Yara Delgado; Alan B Frey
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer.

Authors:  Chen Wang; Mine S Cicek; Bridget Charbonneau; Kimberly R Kalli; Sebastian M Armasu; Melissa C Larson; Gottfried E Konecny; Boris Winterhoff; Jian-Bing Fan; Marina Bibikova; Jeremy Chien; Viji Shridhar; Matthew S Block; Lynn C Hartmann; Daniel W Visscher; Julie M Cunningham; Keith L Knutson; Brooke L Fridley; Ellen L Goode
Journal:  Cancer Res       Date:  2014-04-11       Impact factor: 12.701

10.  Quantification of the CD8+ T cell response against a mucin epitope in patients with breast cancer.

Authors:  Konrad Kokowski; Ulf Harnack; David C Dorn; Gabriele Pecher
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-03-31       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.